ClinicalTrials.gg
TerminatedNCT01512446BILANZUpdated Feb 12, 2019Results posted

Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy

A Phase 3 interventional study of Alendronate and Placebo in Osteoporosis, sponsored by Evangelisches Krankenhaus Lutherhaus gGmbH. Terminated at 1 site in Germany. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-02-12.

Sponsored by Evangelisches Krankenhaus Lutherhaus gGmbH · Phase 3, Interventional, and Treatment

Why this study was terminated
low recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.

Enrollment
3rd of 51
436 · median 60
Started
2012
with 1 other
Phase 3
12 of 51
none open now
Registered
34th of 51
by date

Among the 51 studies testing alendronate in Osteoporosis, this one is the 3rd largest by enrollment, is one of 2 that started in 2012, is one of 12 in phase 3, and was the 34th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alendronate

Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing alendronate in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis.

Read the detailed description

Is a continued treatment with alendronate for another two years after a preceding therapy with bisphosphonates of at least four years able to reduce the incidence of new osteoporotic fractures in patients at high fracture risk compared to a therapy-free interval?

03

Conditions studied

  • Osteoporosis

Keywords

  • Osteoporosis
  • Osteoporotic fractures
  • Bisphosphonate
  • Pretreatment with bisphosphonates
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women or men > 60 years
  • DXA T-Score at lumbar spine, total hip or femur neck \<-2,0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral densitiy
  • Pretreatment with bisphosphonates for at least four years
  • Risk for hip and vertebral fractures min. 30% according to DVO-guideline for osteoporosis 2009
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Other pharmacological treatment of osteoporosis during the last 48 months
  • Other bone diseases
  • Malabsorption syndromes
  • Renal insufficiency with a calculated \< 35 ml/min
  • Diseases of the esophagus, delayed esophageal clearance
  • UUnability to realise the intake instructions
  • Hypocalcemia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
436 participants (actual)

Study arms

  • Active comparator
    Alendronate

    Drug: Alendronate

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 70 mg per week

    Also known as: Fosamax

  • DrugPlacebo

    1 pill per week

06

What researchers measure

Primary outcomes

  1. Number of New Osteoporotic Fractures

    Number of new osteoporotic fractures. All fractures which occurred without high impact trauma (i.e. atraumatically, minor accidents and falls from standing height and lower) were regarded as osteoporotic fractures, except for fractures of fingers, face, skull and toes.

    Time frame: From baseline to study termination (mean duration 5.6 months)

Secondary outcomes

  1. Mortality

    Number of deaths

    Time frame: From baseline to study termination (mean duration 5.6 months)

  2. Combination of New Osteoporotic Fractures and Deaths

    Number of participants with a new osteoporotic fracture or death

    Time frame: From baseline to study termination (mean duration 5.6 months)

07

Results

Posted Jan 17, 2019
Limitations and caveats
Due to a low recruitment rate, the study was early terminated.

Participant flow

The study was early terminated due to a low recruitment rate

Participant flow — Overall Study
MilestonePlaceboAlendronate
Started221215
Safety analysis set197188
Completed00
Not completed221215

Outcome measures

PrimaryNumber of New Osteoporotic Fractures

Number of new osteoporotic fractures. All fractures which occurred without high impact trauma (i.e. atraumatically, minor accidents and falls from standing height and lower) were regarded as osteoporotic fractures, except for fractures of fingers, face, skull and toes.

Time frame:
From baseline to study termination (mean duration 5.6 months)
Reported as:
Number · osteoporotic fractures
Number of New Osteoporotic Fractures
osteoporotic fracturesPlaceboAlendronate
Number of New Osteoporotic Fractures55
SecondaryMortality

Number of deaths

Time frame:
From baseline to study termination (mean duration 5.6 months)
Reported as:
Count of participants · Participants
Mortality
ParticipantsPlaceboAlendronate
Mortality20
SecondaryCombination of New Osteoporotic Fractures and Deaths

Number of participants with a new osteoporotic fracture or death

Time frame:
From baseline to study termination (mean duration 5.6 months)
Reported as:
Count of participants · Participants
Combination of New Osteoporotic Fractures and Deaths
ParticipantsPlaceboAlendronate
Combination of New Osteoporotic Fractures and Deaths75

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—38/197 (19.3%)113/197 (57.4%)
Alendronate—31/188 (16.5%)94/188 (50%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPlaceboAlendronate
Fractured sacrumInjury, poisoning and procedural complications0/1972/188
Sternal fractureInjury, poisoning and procedural complications0/1972/188
Transient ischaemic attackNervous system disorders1/1972/188
Salpingo-oophorectomySurgical and medical procedures0/1972/188
HypertensionVascular disorders1/1972/188
Cardiac failureCardiac disorders2/1971/188
Abdominal pain upperGastrointestinal disorders2/1970/188
Pelvic fractureInjury, poisoning and procedural complications2/1971/188
Knee arthroplastySurgical and medical procedures2/1970/188
MyocarditisCardiac disorders0/1971/188
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboAlendronate
ArthralgiaMusculoskeletal and connective tissue disorders57/19744/188
Musculoskeletal painMusculoskeletal and connective tissue disorders39/19727/188
DizzinessNervous system disorders38/19722/188
FatigueGeneral disorders30/19727/188
HyperhidrosisGeneral disorders30/19721/188
DyspnoeaRespiratory, thoracic and mediastinal disorders28/19714/188
HeadacheNervous system disorders22/19725/188
CoughRespiratory, thoracic and mediastinal disorders24/19714/188
Abdominal pain upperGastrointestinal disorders23/19715/188
ConstipationGastrointestinal disorders23/19711/188

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboAlendronateTotal
Mean75.3 ± 6.974.3 ± 7.174.8 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlendronateTotal
Female194203397
Male271239
Region of Enrollment
Region of Enrollment(Participants)PlaceboAlendronateTotal
Germany221215436
08

Study locations

1 site
  • Department of Internal Medicine III, Alfried Krupp Krankenhaus Essen Steele
    Essen, 45276, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Mar 2013, 13 months.

Results were first posted in Jan 2019, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2012
First posted
Jan 19, 2012
StartActual
Feb 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Jan 17, 2019
Last update
Feb 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01512446
Lead sponsor
Evangelisches Krankenhaus Lutherhaus gGmbH
Collaborators
German Federal Ministry of Education and Research
Responsible party
Prof. Dr. med. Johannes Pfeilschifter (Head of Department of Internal Medicine III, Evangelisches Krankenhaus Lutherhaus gGmbH) — Principal investigator
First posted
Jan 19, 2012
Start date
Feb 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jan 17, 2019
Last update
Feb 12, 2019

Study contacts

Johannes Pfeilschifter, Prof. Dr. med.
study director · Alfried Krupp Krankenhaus Essen Steele

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alendronate

Start the discussion